Table 2.

Serostability for BK and JC human PyV seropositivitya in samples collected longitudinally over time among 210b controls from the Skin Cancer Prevention Study

Controls serostability (n = 210), n (%)
PyVStably seropositiveStably seronegativeSeroconversionSeroreversionFluctuating
BK201 (95.7)6 (2.9)2 (0.9)None1 (0.5)
JC157 (74.8)44 (20.9)6 (2.9)2 (0.9)1 (0.5)
  • aPyV infection was determined using seropositivity for the VP1 protein.

  • bNot including 19 controls who only had a single sample collected. Only controls with ≥2 repeated serum samples were included.